The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI

Exclusion Criteria

• •1. Occurrent liver injury caused by other reasons, such as viral hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease etc;
• •2. Acute liver failure or liver function decompensation patient perform, such as hepatic encephalopathy, ascites, albumin is less than or equal to 35g / L, The international standardized ratio (INR) of thrombin is more than 1.5;
• •3. Serum creatinine is more than 1.5 times ULN;
• •4. Severe or life-threatening heart, lung, brain, kidney, gastrointestinal and systemic diseases;
• •5. Taking drugs that may affect observation of curative effect of the experimental drug during the study;
• •6. Allergy or intolerance to experimental drugs;
• •7. With no ability to express their complaints, such as mental illness and severe neurosis patient;
• •8. The patient can not cooperate and poor compliance;
• •9. Pregnant and lactating women or women preparing for pregnancy;
• •10. The patient participated in other clinical trials in 3 months before entering this study;
• •11. Using other liver-protective drugs except ursodeoxycholic acid or ademetionine within three days;
• •12. The researchers believe not suitable.